Several recent clinical trials have shown that depletion of CCR4-expressing FoxP3+CD4+ Treg cells by anti-human CCR4 monoclonal antibody is a promising approach to augment antitumor immune responses in cancer patients [42, 43]. This evidence concerns the gene FOXP3 and cancer.